J L Arbiser


Affiliation: Emory University
Country: USA


  1. Salehi B, Martorell M, Arbiser J, Sureda A, Martins N, Maurya P, et al. Antioxidants: Positive or Negative Actors?. Biomolecules. 2018;8: pubmed publisher
    ..Hence, the present review aims to provide a nuanced understanding of where current knowledge is and where it should go. ..
  2. Arbiser J, Govindarajan B, Bai X, Onda H, Kazlauskas A, Lim S, et al. Functional tyrosine kinase inhibitor profiling: a generally applicable method points to a novel role of platelet-derived growth factor receptor-beta in tuberous sclerosis. Am J Pathol. 2002;161:781-6 pubmed
    ..Thus, we describe a novel but simple method of determining the functional tyrosine kinase profile of a neoplastic cell and our results suggest that STI571 might be useful in the treatment of neoplasms commonly seen in patients with TS. ..
  3. Arbiser J, Bonner M, Ward N, Elsey J, Rao S. Selenium unmasks protective iron armor: A possible defense against cutaneous inflammation and cancer. Biochim Biophys Acta Gen Subj. 2018;: pubmed publisher
    ..In addition, it offers a novel explanation of how physiologic upregulation of ferroptosis and downregulation of selenoprotein synthesis may mediate resolution of inflammation and carcinogenesis. This is of therapeutic significance. ..
  4. Arbiser J, Yeung R, Weiss S, Arbiser Z, Amin M, Cohen C, et al. The generation and characterization of a cell line derived from a sporadic renal angiomyolipoma: use of telomerase to obtain stable populations of cells from benign neoplasms. Am J Pathol. 2001;159:483-91 pubmed
    ..These cells should serve as a valuable tool to elucidate signal transduction pathways underlying renal angiomyolipomas. ..
  5. request reprint
    Arbiser J, Brat D, Hunter S, D ARMIENTO J, Henske E, Arbiser Z, et al. Tuberous sclerosis-associated lesions of the kidney, brain, and skin are angiogenic neoplasms. J Am Acad Dermatol. 2002;46:376-80 pubmed
    ..Benign neoplasms of patients with tuberous sclerosis are highly vascular. Our results provide a rationale for antiangiogenic therapy in the treatment and prevention of tuberous sclerosis-associated neoplasms. ..
  6. Arbiser J, Kraeft S, van Leeuwen R, Hurwitz S, Selig M, Dickersin G, et al. Clioquinol-zinc chelate: a candidate causative agent of subacute myelo-optic neuropathy. Mol Med. 1998;4:665-70 pubmed
    ..Since clioquinol has been shown to cause increased systemic absorption of zinc in humans, it is likely that clioquinol-zinc chelate was present in appreciable levels in patients with SMON and may be the ultimate causative toxin of SMON. ..
  7. request reprint
    Arbiser J, Weiss S, Arbiser Z, Bravo F, Govindajaran B, Caceres Rios H, et al. Differential expression of active mitogen-activated protein kinase in cutaneous endothelial neoplasms: implications for biologic behavior and response to therapy. J Am Acad Dermatol. 2001;44:193-7 pubmed
    ..Immunohistochemistry for phosphorylated MAPK may help the pathologist distinguish benign from malignant endothelial processes and thus guide therapy. ..
  8. Arbiser J, Elsey J. Targeting the Plasticity of Psoriasis. J Invest Dermatol. 2018;138:734-736 pubmed publisher
    ..No small molecule has been able to compete significantly with topical glucocorticoids, the mainstay of treatment for mild to moderate psoriasis for more than half a century. ..
  9. Arbiser J, Bonner M. Seborrheic Keratoses: The Rodney Dangerfield of Skin lesions, and Why They Should Get Our Respect. J Invest Dermatol. 2016;136:564-566 pubmed publisher
    ..The presence of wild type p53 (seborrheic keratosis) or mutant p53 (cutaneous squamous cell carcinoma) appears to dictate whether a lesion is sensitive to Akt inhibition or not. ..

More Information


  1. Costa A, Bonner M, Arbiser J. Use of Polyphenolic Compounds in Dermatologic Oncology. Am J Clin Dermatol. 2016;17:369-85 pubmed publisher
    ..This review evaluates the existing scientific literature in order to provide support for new research opportunities using polyphenolic compounds in oncodermatology. ..
  2. Mędra A, Witkowska M, Majchrzak A, Cebula Obrzut B, Bonner M, Robak T, et al. Pro-Apoptotic Activity of New Honokiol/Triphenylmethane Analogues in B-Cell Lymphoid Malignancies. Molecules. 2016;21: pubmed publisher
    ..In conclusion, some of the HAs are potent tumor-selective inducers of apoptosis in ex vivo CLL and in BL, DLBCL and MM cells in vitro. Further preclinical studies of these agents are recommended. ..
  3. Arbiser J, Gilbert L. Double Jeopardy: The Rubber Ball Bounces Twice. J Invest Dermatol. 2017;137:15-17 pubmed publisher
    ..This suggests that the remaining normal allele is required for the phenotype. Second, it suggests therapeutic approaches to treatment signal transduction inhibition. ..
  4. Arbiser J, Petros J, Klafter R, Govindajaran B, McLaughlin E, Brown L, et al. Reactive oxygen generated by Nox1 triggers the angiogenic switch. Proc Natl Acad Sci U S A. 2002;99:715-20 pubmed
    ..Nox1 induction of VEGF is eliminated by coexpression of catalase, indicating that hydrogen peroxide signals part of the switch to the angiogenic phenotype. ..
  5. request reprint
    Arbiser J, Bonner M, Berrios R. Hemangiomas, angiosarcomas, and vascular malformations represent the signaling abnormalities of pathogenic angiogenesis. Curr Mol Med. 2009;9:929-34 pubmed
    ..I hypothesize that hemangiomas, angiosarcomas, and vascular malformations represent the extremes of signaling abnormalities seen in pathogenic angiogenesis. ..
  6. Arbiser J, Nowak R, Michaels K, Skabytska Y, Biedermann T, Lewis M, et al. Evidence for biochemical barrier restoration: Topical solenopsin analogs improve inflammation and acanthosis in the KC-Tie2 mouse model of psoriasis. Sci Rep. 2017;7:11198 pubmed publisher
    ..Finally, they stimulated interleukin (IL)-12 production in skin dendritic cells. Thus suggesting barrier restoration has both a biochemical and physical component, and both are necessary for optimal barrier restoration. ..